Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2022 | TIDAL and COASTAL: zandelisib for the treatment of R/R FL and MZL

Wojciech Jurczak • 11 Jun 2022

EHA 2022

Follicular Lymphoma Lymphoma Marginal Zone Lymphoma Non-Hodgkin Lymphoma Antibodies Rituximab Zandelisib

COASTAL TIDAL

Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland talks on the Phase II TIDAL trial (NCT03768505) in which the safety and efficacy of zandelisib, a P13K inhibitor, was assessed in patients with relapsed/refractory follicular lymphoma (R/R FL) or marginal zone lymphoma (MZL) after failure of at least two prior lines of systemic therapy. Moreover, Prof. Jurczak discusses the randomised, Phase III COASTAL trial (NCT04745832) in which zandelisib plus rituximab is compared to standard chemoimmunotherapy in patients with R/R FL or R/R MZL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL

Wojciech Jurczak • 10 Jun 2023

Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCL

Wojciech Jurczak • 10 Jun 2023

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL

Wojciech Jurczak • 10 Jun 2023

Updates on tafasitamab for the treatment of DLBCL

Wojciech Jurczak • 11 Jun 2022

Related Videos

Promising novel immunotherapeutic approaches in lymphoma

Gloria Iacoboni • 15 Apr 2024

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024

Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL

Jacopo Mariotti • 15 Apr 2024

Exciting CAR-T clinical trials in LBCL and FL

Gloria Iacoboni • 15 Apr 2024